This Study is Randomised, Single Oral Dose Bioequivalence Study of Meloxicam GSK 15 MG Tablets.
Status:
Completed
Trial end date:
2013-10-01
Target enrollment:
Participant gender:
Summary
It is a randomized, balanced, open label, crossover, two period, two treatment, two sequence,
single dose, oral bioequivalence study of Meloxicam GSK 15 mg tablets manufactured by
Savipharm J.S.Cc, Vietnam and Mobic® 15 mg tablets of Boehringer Ingelheim Pharma GmbH & Co.
KG Binger Str.173, 5521 Ingelheim am Rhein, Germany, in healthy, adult, human male subjects
under fed condition. It is a pivotal study to demonstrate the bioequivalence of Meloxicam GSK
15 mg tablets manufactured by Savipharm J.S.C, Vietnam and Mobic® 15 mg tablets of Boehringer
Ingelheim Pharma GmbH & Co.KG Binger Str.173, 5521 Ingelheim am Rhein, Germany, in healthy
adult human male subjects under fed condition.
This study will enroll 28 healthy adult human male subjects